Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adoptive immune therapy of chemotherapy-refractory CMV infection with Streptamer-selected T cells after allogeneic HSCT
DRKS00000205Phase 2Recruiting
- Sponsor
- STA Pharmaceutical
- Start
- Sep 2009
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of CMV-specific T cells (University Hospital, Ghent) in cytomegalovirus disease (CMV), sponsored by STA Pharmaceutical. Started Sep 2009; status: recruiting.
02
Drugs
CMV-specific T cells (University Hospital, Ghent)
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on DRKS00000205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00000205.